Listed

Biomarin Pharmaceutical Inc

BMRNNasdaqCIK 1048477HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$989.7mRevenue, Q2 FY2026, three months to 2026-06-30$989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$989.7mRevenue, Q2 FY2026, three months to 2026-06-30$989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure+19.9% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin11.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $110.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure−22.3 pts on a year earlier
  • Net margin4.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $44.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure−24.6 pts on a year earlier
  • Diluted EPS$0.23Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure−81.3% on a year earlier
  • Free cash flow$139.3mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $168.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Capital expenditure: $28.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Report this figure−17.2% on a year earlier

Last eight quarters

Full statements
Revenue$989.7mOperating margin 11.2%
Diluted EPS$0.23, Q2 FY2026
Free cash flow$139.3m, Q2 FY2026
Biomarin Pharmaceutical Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m746Revenue, Q3 FY2024, three months to 2024-09-30$745.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure747Revenue, Q4 FY2024, three months to 2024-12-31$747.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure745Revenue, Q1 FY2025, three months to 2025-03-31$745.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure825Revenue, Q2 FY2025, three months to 2025-06-30$825.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure776Revenue, Q3 FY2025, three months to 2025-09-30$776.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure875Revenue, Q4 FY2025, three months to 2025-12-31$874.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure766Revenue, Q1 FY2026, three months to 2026-03-31$766.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure990Revenue, Q2 FY2026, three months to 2026-06-30$989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%15.3%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $113.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Revenue: $745.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure21.6%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $161.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $747.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure30.0%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $223.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Revenue: $745.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure33.5%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $276.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $825.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure(6.0%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$46.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Revenue: $776.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure(5.1%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$44.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $874.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure16.9%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $129.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Revenue: $766.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure11.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $110.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure
Net margin%14.2%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $106.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Revenue: $745.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure16.7%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $124.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $747.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure24.9%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $185.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Revenue: $745.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure29.1%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $240.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $825.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure(4.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$30.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Revenue: $776.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figure(5.3%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$46.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $874.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure13.8%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $105.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Revenue: $766.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure4.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $44.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Revenue: $989.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure
Diluted EPS$ per share0.55Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figurenot reported (Diluted EPS not reported)0.95Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure1.23Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure(0.16)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0001048477-25-000107.Report this figurenot reported (Diluted EPS not reported)0.54Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure0.23Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001048477-26-000016.Report this figure
Free cash flow$m203Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $221.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0001048477-25-000107. Derived: 9-month figure less the 6-month figure.Capital expenditure: $18.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0001048477-25-000107. Derived: 9-month figure less the 6-month figure.Report this figure166Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $185.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $19.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure158Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $174.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Capital expenditure: $16.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure168Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $185.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Capital expenditure: $17.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Report this figure340Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $368.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0001048477-25-000107. Derived: 9-month figure less the 6-month figure.Capital expenditure: $28.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0001048477-25-000107. Derived: 9-month figure less the 6-month figure.Report this figure58.9Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $99.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $40.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001048477-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure200Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $220.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Capital expenditure: $20.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001048477-26-000008.Report this figure139Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $168.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Capital expenditure: $28.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001048477-26-000016. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$3.22bnOperating margin 12.7%
Diluted EPS$1.80, FY2025
Free cash flow$725.0m, FY2025
Biomarin Pharmaceutical Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,846Revenue, FY2021, twelve months to 2021-12-31$1.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-26, accession 0001048477-24-000016.Report this figure2,096Revenue, FY2022, twelve months to 2022-12-31$2.10bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-24, accession 0001048477-25-000007.Report this figure2,419Revenue, FY2023, twelve months to 2023-12-31$2.42bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure2,854Revenue, FY2024, twelve months to 2024-12-31$2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure3,221Revenue, FY2025, twelve months to 2025-12-31$3.22bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(4.5%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$82.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-26, accession 0001048477-24-000016.Revenue: $1.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-26, accession 0001048477-24-000016.Report this figure7.7%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $161.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-24, accession 0001048477-25-000007.Revenue: $2.10bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-24, accession 0001048477-25-000007.Report this figure7.7%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $185.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $2.42bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure17.0%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $484.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure12.7%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $409.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $3.22bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure
Net margin%(3.5%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$64.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-26, accession 0001048477-24-000016.Revenue: $1.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-26, accession 0001048477-24-000016.Report this figure6.8%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $141.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-24, accession 0001048477-25-000007.Revenue: $2.10bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-24, accession 0001048477-25-000007.Report this figure6.9%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $167.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $2.42bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure15.0%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $426.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $2.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure10.8%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $348.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001048477-26-000004.Revenue: $3.22bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure
Diluted EPS$ per share(0.35)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-26, accession 0001048477-24-000016.Report this figure0.75Diluted EPS, FY2022, twelve months to 2022-12-31$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-24, accession 0001048477-25-000007.Report this figure0.87Diluted EPS, FY2023, twelve months to 2023-12-31$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure2.21Diluted EPS, FY2024, twelve months to 2024-12-31$2.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure1.80Diluted EPS, FY2025, twelve months to 2025-12-31$1.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure
Free cash flow$m209Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $304.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-26, accession 0001048477-24-000016.Capital expenditure: $95.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-26, accession 0001048477-24-000016.Report this figure54.9Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $175.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-24, accession 0001048477-25-000007.Capital expenditure: $121.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-24, accession 0001048477-25-000007.Report this figure62.6Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $159.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001048477-26-000004.Capital expenditure: $96.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure487Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $572.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001048477-26-000004.Capital expenditure: $85.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure725Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $828.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001048477-26-000004.Capital expenditure: $103.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001048477-26-000004.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Biomarin Pharmaceutical Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$1.17bn20,445,212Added+626,911
Dodge & Cox2026-06-30$849.4m14,844,930Added+283,171
PRIMECAP MANAGEMENT CO/CA/2026-06-30$812.0m14,190,183Reduced−3,822
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$500.3m8,743,633Added+100,469
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$494.9m8,648,678Added+350,203
NORGES BANK2026-06-30$469.7m8,207,954New+8,207,954
STATE STREET CORP2026-06-30$446.4m7,800,959Added+505,880
VIKING GLOBAL INVESTORS LP2026-06-30$435.8m7,616,563Added+554,486
Vestal Point Capital, LP2026-06-30$344.8m6,025,000Added+2,450,000
AQR CAPITAL MANAGEMENT LLC2026-06-30$322.5m5,699,541Reduced−1,977,000

Recent filings

All 2,042 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Biomarin Pharmaceutical Inc, recent filings
FiledFormWhat it isAccession number
2026-10-0620:22 ET8-K2.02 Results of operations0001048477-26-000019
2026-09-3020:15 ET8-K1.01 Entry into a material agreement0001628280-26-063981
2026-09-1512:31 ET8-K8.01 Other events0001628280-26-061973
2026-09-1413:26 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-061717
2026-09-0113:23 ET8-K8.01 Other events0001193125-26-377696
2026-08-3110:01 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-375275
2026-08-1812:39 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-354780
2026-08-0620:14 ET10-QQuarterly reportPeriod 2026-06-300001048477-26-000016
2026-08-0620:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001048477-26-000015
2026-07-1320:06 ET8-K/A8.01 Other events; 9.01 Financial statements and exhibits0001048477-26-000011

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1048477
Tickers
BMRN
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. Listed shows no prices and gives no investment advice.